Welcome to Novo Nordisk Science Hub
The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Mary E. Rinella is a Professor of Medicine at the University of Chicago Pritzker School of Medicine and is the Director of the Metabolic and Fatty Liver Program. Currently her focus is in clinical research in the area of non-alcoholic fatty liver disease (NAFLD)/Nonalcoholic steatohepatitis (NASH) both before and after liver transplantation. Dr. Rinella is actively involved in the American Association for the Study of Liver Diseases (AASLD) where she recently served as Councilor-at-large on the Governing Board. She was an author on the 2018 AASLD Practice Guidance for NAFLD and the chair of the 2023 AASLD NAFLD Practice Guidance. She has held several national leadership roles in the field of NAFLD including Chair of the AASLD NAFLD Special Interest Group (SIG) and currently as Chair of the AASLD NASH Task Force. She is the former chair of the NASH task force and current chair of the new AASLD steatotic liver disease task force. As former chair of the NASH Task Force, she was charged with fostering research collaboration and advancing best practice through collaboration with other medical societies, federal agencies and patient advocacy organizations to improve outcomes in patients with NASH.
Aleksander Krag
Odense University Hospital, Odense, Denmark
Aleksander Krag, MD, PhD, MBA is Professor and Department Chair, Department of Gastroenterology and Hepatology Odense University Hospital, Director of Centre for Liver Research (FLASH) Odense University Hospital and DIAS Chair of Health Sciences, University of Southern Denmark. Also serves as Vice Secretary General, European Association for the Study of Liver (EASL) and is the incoming Secretary General 2023-2025.
Read full bio
Salvatore Petta
University of Palermo, Palermo, Italy
Salvatore Petta obtained Degree in Medicine at the University of Palermo on July 2002, and then at the same University he became a Specialist in Gastroenterology on December 2006, PhD on Biopathology on March 2010, and Associate Professor of Gastroenterology since November 2019.
Dr Petta was/is principal-investigator in different clinical trials on chronic hepatitis C and Non-alcoholic steatohepatitis. He is the author of more than 200 peer-reviewed papers published in international journals.
He was Secretary of AISF (Italian association for the study of the liver) and member of EASL. His main areas of clinical and research interest are viral hepatitis and non-alcoholic fatty liver disease. He was speaker at different national and international scientific meetings, also acts as a reviewer for the EASL International Liver Congress, and as referee of papers published in international journals, and also acts as an associate editor for Liver International. He participated in writing 2021 European guidelines on noninvasive tests in chronic liver diseases, and 2021 Italian guidelines on management of Nonalcoholic fatty liver disease.
Read full bio